Advertisement

The U.S. Food and Drug Administration has granted a total of three approvals to Natick medical devices company Boston Scientific Corp. for devices targeting treatment of heart failure and sudden cardiac death. The devices – Incepta, Energen and Punctua cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs) – have already seen their first implant with the Incepta ICD at the University of Washington Medical Center in Seattle.

SOURCE

Advertisement
Advertisement